Related Experiment Video
Updated: Aug 12, 2026
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
The management of thrombotic thrombocytopenic purpura in 2005
1Division of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada. grock@ottawahospital.on.ca
Thrombotic thrombocytopenic purpura is an uncommon disease that often presents with a striking and acute clinical picture. Although first described more than 80 years ago, the therapy has changed little since the discovery that plasma, and then plasma exchange, could bring about a remarkable response, changing survival rates from 20% to more than 80%. However, although plasma exchange is now considered the standard of care, there is still considerable discussion concerning the appropriate schedules for therapy and the types of fluids that should be used. Because plasma exchange (PE) is not effective in all patients, and at least 30% of patients will have one or more relapses, several adjuvant therapies have also been used. Most recently, this has included the use of rituximab to achieve an immunomodulatory effect.
Thrombotic thrombocytopenic purpura is an uncommon disease that often presents with a striking and acute clinical picture. Although first described more than 80 years ago, the therapy has changed little since the discovery that plasma, and then plasma exchange, could bring about a remarkable response, changing survival rates from 20% to more than 80%. However, although plasma exchange is now considered the standard of care, there is still considerable discussion concerning the appropriate schedules for therapy and the types of fluids that should be used. Because plasma exchange (PE) is not effective in all patients, and at least 30% of patients will have one or more relapses, several adjuvant therapies have also been used. Most recently, this has included the use of rituximab to achieve an immunomodulatory effect.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care